|
1
|
Parkin DM, Pisani P and Ferlay J: Global
cancer statistics. CA Cancer J Clin. 49:33–64. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rose PG: Chemoradiotherapy: The new
standard care for invasive cervical cancer. Drugs. 60:1239–1244.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Iyer RB, Balachandran A and Devine CE:
PET/CT and cross sectional imaging of gynecologic malignancy.
Cancer Imaging. 7:S130–S138. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mirpour S, Mhlanga JC, Logeswaran P, Russo
G, Mercier G and Subramaniam RM: The role of PET/CT in the
management of cervical cancer. AJR Am J Roentgenology.
201:W192–W205. 2013. View Article : Google Scholar
|
|
5
|
Quinn MA, Benedet JL, Odicino F,
Maisonneuve P, Beller U, Creasman WT, Heintz AP, Ngan HY and
Pecorelli S: Carcinoma of the cervix uteri. FIGO 26th annual report
on the results of treatment in gynecological cancer. Int J Gynaecol
Obstet. 95(Suppl 1): S43–S103. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Guo L, Liu X, Wang L, Sun H, Huang K, Li
X, Tang F, Li S, Yuan X and Wang C: Outcome of international
federation of gynecology and obstetrics stage iib cervical cancer
from 2003 to 2012: An evaluation of treatments and prognosis: A
retrospective study. Int J Gynecol Cancer. 25:910–918. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ellenson LH and Wu TC: Focus on
endometrial and cervical cancer. Cancer Cell. 5:533–538. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zaino RJ, Ward S, Delgado G, Bundy B, Gore
H, Fetter G, Ganjei P and Frauenhoffer E: Histopathologic
predictors of the behavior of surgically treated stage IB squamous
cell carcinoma of the cervix. A Gynecologic Oncology Group study.
Cancer. 69:1750–1758. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Baalbergen A, Ewing-Graham PC, Hop WC,
Struijk P and Helmerhorst TJ: Prognostic factors in adenocarcinoma
of the uterine cervix. Gynecologic Oncol. 92:262–267. 2004.
View Article : Google Scholar
|
|
10
|
Zhao Q, Feng Y, Mao X and Qie M:
Prognostic value of fluorine-18-fluorodeoxyglucose positron
emission tomography or PET-computed tomography in cervical cancer:
A meta-analysis. Int J Gynecol Cancer. 23:1184–1190. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wahl RL, Jacene H, Kasamon Y and Lodge MA:
From RECIST to PERCIST: Evolving considerations for PET response
criteria in solid tumors. J Nucl Med. 50(Suppl l): S122–S150. 2009.
View Article : Google Scholar
|
|
12
|
Michaelis LC and Ratain MJ: Measuring
response in a post-RECIST world: From black and white to shades of
grey. Nat Rev Cancer. 6:409–414. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Stefano A, Russo G, Ippolito M, Cosentino
S, Murè G, Baldari S, Sabini MG, Sardina D, Valastro LM, Bordonaro
R, et al: Evaluation of erlotinib treatment response in non-small
cell lung cancer using metabolic and anatomic criteria. Q J Nucl
Med Mol Imaging. May 9–2014.(Epub ahead of print).
|
|
14
|
Heron DE, Andrade RS, Beriwal S and Smith
RP: PET-CT in radiation oncology: The impact on diagnosis,
treatment planning and assessment of treatment response. Am J Clin
Oncol. 31:352–362. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bar-Shalom R, Yefremov N, Guralnik L,
Gaitini D, Frenkel A, Kuten A, Altman H, Keidar Z and Israel O:
Clinical performance of PET/CT in evaluation of cancer: Additional
value for diagnostic imaging and patient management. J Nuc Med.
44:1200–1209. 2003.
|
|
16
|
Tanvetyanon T, Eikman EA, Sommers E,
Robinson L, Boulware D and Bepler G: Computed tomography response,
but not positron emission tomography scan response, predicts
survival after neoadjuvant chemotherapy for resectable
non-small-cell lung cancer. J Clin Oncol. 26:4610–4616. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hoekstra CJ, Stroobants SG, Smit EF,
Vansteenkiste J, van Tinteren H, Postmus PE, Golding RP, Biesma B,
Schramel FJ, van Zandwijk N, et al: Prognostic relevance of
response evaluation using (18F)-2-fluoro-2-deoxy-D-glucose positron
emission tomography in patients with locally advanced
non-small-cell lung cancer. J Clin Oncol. 23:8362–8370. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Young H, Baum R, Cremerius U, Herholz K,
Hoekstra O, Lammertsma AA, Pruim J and Price P: Measurement of
clinical and subclinical tumour response using
(18F)-fluorodeoxyglucose and positron emission tomography: Review
and 1999 EORTC recommendations. European organization for research
and treatment of cancer (EORTC) PET study group. Eur J Cancer.
35:1773–1782. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rahim MK, Kim SE, So H, Kim HJ, Cheon GJ,
Lee ES, Kang KW and Lee DS: Recent Trends in pet image
interpretations using volumetric and texture-based quantification
methods in nuclear oncology. Nucl Med Mol Imaging. 48:1–15. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kwee TC, Basu S, Saboury B, Ambrosini V,
Torigian DA and Alavi A: A new dimension of FDG-PET interpretation:
Assessment of tumor biology. Eur J Nucl Med Mol Imaging.
38:1158–1170. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kidd EA, Spencer CR, Huettner PC, Siegel
BA, Dehdashti F, Rader JS and Grigsby PW: Cervical cancer histology
and tumor differentiation affect 18F-fluorodeoxyglucose uptake.
Cancer. 115:3548–3554. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Larson SM, Erdi Y, Akhurst T, Mazumdar M,
Macapinlac HA, Finn RD, Casilla C, Fazzari M, Srivastava N, Yeung
HW, et al: Tumor treatment response based on visual and
quantitative changes in global tumor glycolysis using PET-FDG
imaging. The visual response score and the change in total lesion
glycolysis. Clin Positron Imaging. 2:159–171. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zaidi H and El Naqa I: PET-guided
delineation of radiation therapy treatment volumes: A survey of
image segmentation techniques. Eur J Nucl Med Mol Imaging.
37:2165–2187. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kim BS, Kim IJ, Kim SJ, Nam HY, Pak KJ,
Kim K and Yun MS: The prognostic value of the metabolic tumor
volume in FIGO stage IA to IIB cervical cancer for tumor
recurrence: Measured by F-18 FDG PET/CT. Nucl Med Mol Imaging.
45:36–42. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kidd EA, El Naqa I, Siegel BA, Dehdashti F
and Grigsby PW: FDG-PET-based prognostic nomograms for locally
advanced cervical cancer. Gynecol Oncol. 127:136–140. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lee HY, Hyun SH, Lee KS, Kim BT, Kim J,
Shim YM, Ahn MJ, Kim TS, Yi CA and Chung MJ: Volume-based parameter
of 18)F-FDG PET/CT in malignant pleural mesothelioma: Prediction of
therapeutic response and prognostic implications. Ann Surg Oncol.
17:2787–2794. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Costelloe CM, Macapinlac HA, Madewell JE,
Fitzgerald NE, Mawlawi OR, Rohren EM, Raymond AK, Lewis VO,
Anderson PM, Bassett RL Jr, et al: 18F-FDG PET/CT as an indicator
of progression-free and overall survival in osteosarcoma. J Nucl
Med. 50:340–347. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xie P, Yue JB, Zhao HX, Sun XD, Kong L, Fu
Z and Yu JM: Prognostic value of 18F-FDG PET-CT metabolic index for
nasopharyngeal carcinoma. J Cancer Res Clin Oncol. 136:883–889.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yoo J, Choi JY, Lee KT, Heo JS, Park SB,
Moon SH, Choe YS, Lee KH and Kim BT: Prognostic Significance of
volume-based metabolic parameters by (18)F-FDG PET/CT in
Gallbladder Carcinoma. Nucl Med Mol Imaging. 46:201–206. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Stefano A: Metabolic response assessment
in non-small cell lung cancer patients after platinum-based
therapy: A preliminary analysis. Curr Med Imaging Rev. 11:218–217.
2015. View Article : Google Scholar
|
|
32
|
Yoo J, Choi JY, Moon SH, Bae DS, Park S,
Choe YS, Lee KH and Kim BT: Prognostic significance of volume-based
metabolic parameters in uterine cervical cancer determined using
18F-fluorodeoxyglucose positron emission tomography. Int J Gynecol
Cancer. 22:1226–1233. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Miccò M, Vargas HA, Burger IA, Kollmeier
MA, Goldman DA, Park KJ, Abu-Rustum NR, Hricak H and Sala E:
Combined pre-treatment MRI and 18F-FDG PET/CT parameters as
prognostic biomarkers in patients with cervical cancer. Eur J
Radiol. 83:1169–1176. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liao S, Lan X, Cao G, Yuan H and Zhang Y:
Prognostic predictive value of total lesion glycolysis from 18F-Fdg
Pet/Ct in post-surgical patients with epithelial ovarian cancer.
Clin Nucl Med. 38:715–720. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yen TC, See LC, Lai CH, Yah-Huei CW, Ng
KK, Ma SY, Lin WJ, Chen JT, Chen WJ, Lai CR and Hsueh S: 18F-FDG
uptake in squamous cell carcinoma of the cervix is correlated with
glucose transporter 1 expression. J Nucl Med. 45:22–29.
2004.PubMed/NCBI
|
|
36
|
Park JO, Lee Sl, Song SY, Kim K, Kim WS,
Jung CW, Park YS, Im YH, Kang WK, Lee MH, et al: Measuring response
in solid tumors: Comparison of RECIST and WHO response criteria.
Jpn J Clin Oncol. 33:533–537. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Stefano A, Vitabile S, Russo G, Ippolito
M, Sardina D, Sabini MG, et al: A graph-based method for PET image
segmentation in radiotherapy planning: A pilot study. Image
Analysis and Processing - ICIAP 2013. Petrosino A: Springer-Verlag.
(Berlin). 711–720. 2013. View Article : Google Scholar
|
|
38
|
Kurman JR: Tumors of the cervix, vagina
and vulva. Afip Atlas of Tumor Pathology. 5:(4th). Silverberg SG:
ARP Press Washington. (WA, USA). 1142010.
|
|
39
|
Kidd EA, Siegel BA, Dehdashti F and
Grigsby PW: The standardized uptake value for F-18
fluorodeoxyglucose is a sensitive predictive biomarker for cervical
cancer treatment response and survival. Cancer. 110:1738–1744.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Husain A, Akhurst T, Larson S, Alektiar K,
Barakat RR and Chi DS: A prospective study of the accuracy of
18Fluorodeoxyglucose positron emission tomography (18FDG PET) in
identifying sites of metastasis prior to pelvic exenteration.
Gynecol Oncol. 106:177–180. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Konishi H, Takehara K, Kojima A, Okame S,
Yamamoto Y, Shiroyama Y, Yokoyama T, Nogawa T and Sugawara Y:
Maximum standardized uptake value of fluorodeoxyglucose positron
emission tomography/computed tomography is a prognostic factor in
ovarian clear cell adenocarcinoma. Int J Gynecol Cancer.
24:1190–1194. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Xue F, Lin LL, Dehdashti F, Miller TR,
Siegel BA and Grigsby PW: F-18 fluorodeoxyglucose uptake in primary
cervical cancer as an indicator of prognosis after radiation
therapy. Gynecol Oncol. 101:147–151. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Stefano A, Gallivanone F, Messa C, Gilardi
MC and Castiglioni I: Metabolic impact of partial volume correction
of (18F) FDG PET-CT oncological studies on the assessment of tumor
response to treatment. Q J Nucl Med Mol Imaging. 58:413–423.
2014.PubMed/NCBI
|
|
44
|
Shankar LK, Hoffman JM, Bacharach S,
Graham MM, Karp J, Lammertsma AA, et al: Consensus recommendations
for the use of F-18-FDG PET as an indicator of therapeutic response
in patients in national cancer institute trials. J Nucl Med.
47:1059–1066. 2006.PubMed/NCBI
|
|
45
|
Boellaard R, O'Doherty MJ, Weber WA,
Mottaghy FM, Lonsdale MN, Stroobants SG, Oyen WJ, Kotzerke J,
Hoekstra OS, Pruim J, et al: FDG PET and PET/CT: EANM procedure
guidelines for tumour PET imaging: Version 1.0. Eur J Nucl Med Mol
Imaging. 37:181–200. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Grueneisen J, Schaarschmidt BM, Heubner M,
Aktas B, Kinner S, Forsting M, Lauenstein T, Ruhlmann V and Umutlu
L: Integrated PET/MRI for whole-body staging of patients with
primary cervical cancer: preliminary results. Eur J Nucl Med Mol
Imaging. 42:1814–1824. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kurokawa T, Yoshida Y, Kawahara K,
Tsuchida T, Okazawa H, Fujibayashi Y, Yonekura Y and Kotsuji F:
Expression of GLUT-1 glucose transfer, cellular proliferation
activity and grade of tumor correlate with
(F-18)-fluorodeoxyglucose uptake by positron emission tomography in
epithelial tumors of the ovary. Int J Cancer. 109:926–932. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Dhull VS, Sharma P, Sharma DN, Maharjan S,
Suman KCS, Patel C, Bal C and Kumar R: Prospective evaluation of
18F-fluorodeoxyglucose positron emission tomography-computed
tomography for response evaluation in recurrent carcinoma cervix:
Does metabolic response predicts survival? Int J Gynecol Cancer.
24:312–320. 2014. View Article : Google Scholar : PubMed/NCBI
|
